Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425380 · ClinicalTrials.gov registry record · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
A NA study of Cirrhosis and Hepatic Encephalopathy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT06425380: Recruiting NA study of Cirrhosis and Hepatic Encephalopathy, sponsored by Mayo Clinic.
NCT06425380 is a NA study of Cirrhosis and Hepatic Encephalopathy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 11 participants, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06425380, a NA study of Cirrhosis and Hepatic Encephalopathy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy. The researchers in this study want to understand how potato starch works in the subject's body and how the body will react to it. Along with taking the study product participants health-related information and stool will be collected for this research study.
Primary Outcome
The study team will compare the total concentrations of the 3 most abundant SCFAs in humans (acetate, propionate, and butyrate) at baseline and week 4. Stool will undergo SCFA quantification by the University of Michigan Metabolomics core.
Conditions Studied
Interventions
- OTHER Resistant Potato Starch
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2027-01-28 |
| Phase | NA |
What NCT06425380 shows while recruiting
NCT06425380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which Resistant Potato Starch is the first listed.
NCT06425380 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06425380 about?
NCT06425380 is a clinical study titled "Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy". This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy. The researchers in this study want to understand how potato starch works in the subject's body a...
What is the current status of trial NCT06425380?
This trial is currently recruiting. It is a NA study. The enrollment target is 11 participants. The study started on 2024-07-12. Estimated completion is 2027-01-28.
What conditions does trial NCT06425380 study?
This clinical trial studies the following conditions: Cirrhosis, Hepatic Encephalopathy.
What interventions are being tested in trial NCT06425380?
The interventions under investigation include: Resistant Potato Starch (OTHER).
Who is sponsoring clinical trial NCT06425380?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425380 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06425380's enrollment target sits among peer trials
11 51st of 53 higher than 3 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
CirrhosisRx CDS System
RECRUITING · NA
-
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
RECRUITING · NA
-
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
- NCT06673329 · 11 participants · Phase 1
Brodalumab in the Treatment of Immune-Related Adverse Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI